78 related articles for article (PubMed ID: 2847262)
1. A structure-activity relationship study on papaverine analogs.
Gupta SP; Garg C; Gupta JK
Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):265-8. PubMed ID: 2847262
[TBL] [Abstract][Full Text] [Related]
2. Effect of papaverine analogues on 3', 5'-adenosine monophosphate phosphodiesterase activity in rat brain.
Stancheva S; Uzunov P; Stoytchev T
Acta Physiol Pharmacol Bulg; 1980; 6(1):41-7. PubMed ID: 6250318
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine.
Mannhold R
Arzneimittelforschung; 1988 Dec; 38(12):1806-8. PubMed ID: 2854468
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of adenosine 3',5'-monophosphate phosphodiesterase by nicotinamide and its homologues in vitro.
Shimoyama M; Kawai M; Nasu S; Shioji K; Hoshi Y
Physiol Chem Phys; 1975; 7(2):125-32. PubMed ID: 239431
[TBL] [Abstract][Full Text] [Related]
5. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
6. Inhibition of cyclic AMP phosphodiesterases by cyclic nucleotide analogs and nitrogen heterocycles.
Miller JP; Sigman CC; Johnson HL; Novinson T; Springer RH; Senga K; O'Brien DE; Robins RK
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():277-90. PubMed ID: 6326528
[No Abstract] [Full Text] [Related]
7. 1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors.
Walker KA; Boots MR; Stubbins JF; Rogers ME; Davis CW
J Med Chem; 1983 Feb; 26(2):174-81. PubMed ID: 6298424
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
Ilien B; Ruckstuhl M; Landry Y
J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
[TBL] [Abstract][Full Text] [Related]
9. Correlation of biological activities of mesoionic and benz-fused mesoionic xanthine analogs with van der Waals volume and molecular connectivity.
Prabhakar YS; Handa A; Gupta SP
J Pharmacobiodyn; 1984 Jun; 7(6):366-71. PubMed ID: 6090634
[TBL] [Abstract][Full Text] [Related]
10. [Interaction between cyclic adenosine-3':5'-monophosphate phosphodiesterase and structural analogs of the substrate].
Kochetkova MN; Guliaev NN; Tunitskaia VL; Severin ES
Biokhimiia; 1981 Feb; 46(2):353-60. PubMed ID: 6264977
[TBL] [Abstract][Full Text] [Related]
11. Interaction of four methylxanthine compounds and norepinephrine on cardiac phosphorylase activation and cardiac contractility.
McNeill JH; Brenner MJ; Muschek LD
Recent Adv Stud Cardiac Struct Metab; 1973; 3():261-73. PubMed ID: 4377599
[No Abstract] [Full Text] [Related]
12. Effect of some phosphodiesterase inhibitors on two different preparations of adenosine 3',5'-monophosphate phosphodiesterase.
Du Moulin A; Schultz J
Experientia; 1975 Aug; 31(8):883-4. PubMed ID: 169139
[No Abstract] [Full Text] [Related]
13. Cyclic AMP phosphodiesterase inhibition by coumarins and furanocoumarins.
Sardari S; Nishibe S; Horita K; Nikaido T; Daneshtalab M
Pharmazie; 1999 Jul; 54(7):554-6. PubMed ID: 10445247
[No Abstract] [Full Text] [Related]
14. [Antiphosphodiesterase activity of papaveroline/sulfonic acid. In vitro spectrophotometric determination].
Castellani G; Zagaria F
Farmaco Prat; 1978; 33(4):187-93. PubMed ID: 215448
[No Abstract] [Full Text] [Related]
15. Relationships between structure and vascular activity in a series of benzylisoquinolines.
Chulia S; Ivorra MD; Martinez S; Elorriaga M; Valiente M; Noguera MA; Lugnier C; Advenier C; D'Ocon P
Br J Pharmacol; 1997 Oct; 122(3):409-16. PubMed ID: 9351495
[TBL] [Abstract][Full Text] [Related]
16. Structure/activity studies of flavonoids as inhibitors of cyclic AMP phosphodiesterase and relationship to quantum chemical indices.
Ferrell JE; Chang Sing PD; Loew G; King R; Mansour JM; Mansour TE
Mol Pharmacol; 1979 Sep; 16(2):556-68. PubMed ID: 229402
[No Abstract] [Full Text] [Related]
17. Effect of cyclic AMP phosphodiesterase inhibitors on cardiac sarcolemmal 5'-nucleotidase.
Heyliger CE; Panagia V; Dhalla NS
J Pharmacol Exp Ther; 1981 May; 217(2):489-93. PubMed ID: 6262487
[TBL] [Abstract][Full Text] [Related]
18. 9-Benzyladenines: potent and selective cAMP phosphodiesterase inhibitors.
Bourguignon JJ; Désaubry L; Raboisson P; Wermuth CG; Lugnier C
J Med Chem; 1997 Jun; 40(12):1768-70. PubMed ID: 9191951
[No Abstract] [Full Text] [Related]
19. Enaminones 9. Further studies on the anticonvulsant activity and potential type IV phosphodiesterase inhibitory activity of substituted vinylic benzamides.
Anderson AJ; Nicholson JM; Bakare O; Butcher RJ; Wilson TL; Scott KR
Bioorg Med Chem; 2006 Feb; 14(4):997-1006. PubMed ID: 16219468
[TBL] [Abstract][Full Text] [Related]
20. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
